Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

by rvvadmin | Dec 15, 2025 | 2025

TORONTO, Dec. 15, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

by rvvadmin | Nov 21, 2025 | 2025

TORONTO, Nov. 21, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical...

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

by rvvadmin | Sep 19, 2025 | 2025

TORONTO, Sept. 19, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed...

Revive Therapeutics Announces Extension of Proposed Private Placement

by rvvadmin | Sep 5, 2025 | 2025

TORONTO, Sept. 05, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it is...

Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

by rvvadmin | Aug 11, 2025 | 2025

TORONTO, Aug. 11, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed...